Free tool
FAERS Monitor: Rituxan
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 103705 or its brand name (Rituxan, Rituximab). Reports on generic versions are filed under their own applications.
Reports
214,105
Serious
191,594
89% of reports
Hospitalization
69,231
Death reported
37,921
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use41,722
- drug ineffective34,408
- rheumatoid arthritis20,327
- pain17,935
- fatigue17,483
- rash13,683
- arthralgia13,466
- pneumonia13,256
- infusion related reaction12,870
- drug intolerance12,675
- joint swelling12,000
- pyrexia11,912
- nausea11,843
- infection11,292
- alopecia10,955
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 508 |
| 2005 | 739 |
| 2006 | 724 |
| 2007 | 1,256 |
| 2008 | 1,417 |
| 2009 | 2,038 |
| 2010 | 2,486 |
| 2011 | 3,186 |
| 2012 | 4,694 |
| 2013 | 4,805 |
| 2014 | 5,019 |
| 2015 | 5,951 |
| 2016 | 6,768 |
| 2017 | 11,206 |
| 2018 | 12,326 |
| 2019 | 14,980 |
| 2020 | 20,539 |
| 2021 | 18,597 |
| 2022 | 21,328 |
| 2023 | 20,221 |
| 2024 | 24,171 |
| 2025 | 18,885 |
| 2026 | 12,260 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,840,054 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infusion related reactionSignal | 12,870 | 23.4 | 23.0 | 223,360 |
| rheumatoid arthritisSignal | 20,327 | 21.2 | 20.9 | 323,022 |
| drug intoleranceSignal | 12,675 | 14.7 | 14.4 | 141,070 |
| joint swellingSignal | 12,000 | 10.7 | 10.5 | 95,931 |
| infectionSignal | 11,292 | 8.2 | 8.1 | 66,558 |
| alopeciaSignal | 10,955 | 5.7 | 5.6 | 40,912 |
| off label useSignal | 41,722 | 4.9 | 4.8 | 127,296 |
| pneumoniaSignal | 13,256 | 4.2 | 4.1 | 30,883 |
| pyrexiaSignal | 11,912 | 3.5 | 3.4 | 20,524 |
| arthralgiaSignal | 13,466 | 3.3 | 3.2 | 20,759 |
| rashSignal | 13,683 | 3.2 | 3.1 | 19,873 |
| painSignal | 17,935 | 2.9 | 2.9 | 22,710 |
| drug ineffectiveSignal | 34,408 | 2.6 | 2.6 | 35,401 |
| fatigueSignal | 17,483 | 2.2 | 2.2 | 12,091 |
| nausea | 11,843 | 1.5 | 1.5 | 1,868 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.